VBP
Chiesi UK and Ireland supports NHS workforce to address COPD diagnosis backlog
An estimated two million people in the UK are living with undiagnosed chronic obstructive pulmonary disease
J&J’s Darzalex combination treatment for untreated multiple myeloma recommended by NICE
Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer
NICE recommends axunio’s Axhidrox cream for adults with severe hyperhydrosis
Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life
NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia
The treatments are for eligible adults in England and Wales
Number of women in England receiving HRT on the NHS more than doubles
A record two million women were prescribed hormone replacement therapy in 2025/26 compared to 0.8 million in 2020/21
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer
It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year
Durbin PLC becomes Uniphar, bolstering medicine access amidst growing healthcare demands
Against the backdrop of widespread medicine shortages, Durbin PLC’s rebrand to Uniphar and integration into Uniphar | Global Sourcing represents a strategic move to address industry-wide challenges, expanding its sourcing...
Incyte Biosciences UK announces NICE approval for Opzelura for vitiligo
This is the first approved treatment option in the UK for patients with non-segmental vitiligo
Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD
Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed
UK and US agree on landmark pharma pricing tariff deal
US tariffs on UK-produced pharmaceuticals will remain at zero for three years
ViiV Healthcare receives NICE recommendation for HIV prevention therapy
The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales